Cambridge Investment Research Advisors
OTLK icon

Cambridge Investment Research Advisors’s Outlook Therapeutics OTLK Stock Holding History

Cambridge Investment Research Advisors’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-500
Closed -$13K – 2576
2020
Q2 		$13K Buy
+500
New +$8.92K ﹤0.01% 2443

Other funds holding OTLK

LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Cambridge Investment Research Advisors's OTLK Position: Q3 2020 in Review

Cambridge Investment Research Advisors sold out of Outlook Therapeutics (OTLK) in Q3 2020, closing a stake of 500 shares — an estimated $13K sold.

Cambridge Investment Research Advisors first reported a position in OTLK in Q2 2020 and held it in 1 quarter. The position peaked at $13K in Q2 2020. 27 funds tracked by Wall St. Rank hold OTLK as of Q3 2020.

  • Cambridge Investment Research Advisors reported no remaining Outlook Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 500 Outlook Therapeutics shares in Q3 2020, an estimated $13K.
  • Cambridge Investment Research Advisors first reported a position in Outlook Therapeutics in Q2 2020 and held it in 1 quarter.
  • Cambridge Investment Research Advisors's Outlook Therapeutics position peaked at $13K in Q2 2020.
  • 27 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2020.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2020, filed 29 Oct 2020.